GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (BOM:532488) » Definitions » Capex-to-Revenue

Divi's Laboratories (BOM:532488) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Divi's Laboratories's Capital Expenditure for the three months ended in Sep. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was ₹23,380.00 Mil.

Hence, Divi's Laboratories's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.00.


Divi's Laboratories Capex-to-Revenue Historical Data

The historical data trend for Divi's Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories Capex-to-Revenue Chart

Divi's Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.13 0.08 0.06 0.13

Divi's Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Divi's Laboratories's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Capex-to-Revenue falls into.



Divi's Laboratories Capex-to-Revenue Calculation

Divi's Laboratories's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-10030) / 77960
=0.13

Divi's Laboratories's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 23380
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories  (BOM:532488) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Divi's Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories Business Description

Traded in Other Exchanges
Address
Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients with a predominance in exports. It also through its custom synthesis, supports pharma companies for their patented products business from gram scale requirements for clinical trials to launch as well as late life cycle management. Geographically, the company derives a majority of its revenue through exports to countries like the United States of America, Switzerland, and other countries.

Divi's Laboratories Headlines

No Headlines